Clinical Trial Update: Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of GR2001 in Chinese Healthy Adults [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update on GR2001 evaluating safety, tolerability, PK/PD and immunogenicity in healthy Chinese adults for tetanus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tetanus

Drugs mentioned

• GR2001

Snippet

Sponsor: Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Conditions: Tetanus | Phase 1, Phase 2 | Status: COMPLETED